JP2013514979A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514979A5
JP2013514979A5 JP2012544851A JP2012544851A JP2013514979A5 JP 2013514979 A5 JP2013514979 A5 JP 2013514979A5 JP 2012544851 A JP2012544851 A JP 2012544851A JP 2012544851 A JP2012544851 A JP 2012544851A JP 2013514979 A5 JP2013514979 A5 JP 2013514979A5
Authority
JP
Japan
Prior art keywords
mesalamine
suppository
measured
dissolution
rectal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012544851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514979A (ja
Filing date
Publication date
Priority claimed from US12/639,645 external-priority patent/US8436051B2/en
Application filed filed Critical
Publication of JP2013514979A publication Critical patent/JP2013514979A/ja
Publication of JP2013514979A5 publication Critical patent/JP2013514979A5/ja
Pending legal-status Critical Current

Links

JP2012544851A 2009-12-16 2010-12-16 メサラミン坐剤 Pending JP2013514979A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/639,645 US8436051B2 (en) 2007-06-08 2009-12-16 Mesalamine suppository
US12/639,645 2009-12-16
PCT/US2010/060849 WO2011084638A2 (en) 2009-12-16 2010-12-16 Mesalamine suppository

Publications (2)

Publication Number Publication Date
JP2013514979A JP2013514979A (ja) 2013-05-02
JP2013514979A5 true JP2013514979A5 (OSRAM) 2014-02-13

Family

ID=43901620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544851A Pending JP2013514979A (ja) 2009-12-16 2010-12-16 メサラミン坐剤

Country Status (14)

Country Link
US (2) US8436051B2 (OSRAM)
EP (1) EP2512443A2 (OSRAM)
JP (1) JP2013514979A (OSRAM)
KR (1) KR20120104604A (OSRAM)
CN (1) CN102970971A (OSRAM)
AU (1) AU2010339837A1 (OSRAM)
CA (2) CA2690450A1 (OSRAM)
CL (1) CL2012001636A1 (OSRAM)
IL (1) IL220397A0 (OSRAM)
MX (1) MX2012006902A (OSRAM)
RU (1) RU2012125186A (OSRAM)
SG (1) SG181169A1 (OSRAM)
WO (1) WO2011084638A2 (OSRAM)
ZA (1) ZA201204422B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
PL2166128T3 (pl) 2008-09-19 2012-05-31 Oerlikon Trading Ag Sposób wytwarzania powłok z tlenków metali przez naparowywanie łukowe
WO2012032185A1 (de) * 2010-09-10 2012-03-15 Pharmazell Gmbh Verfahren zur herstellung kristalliner 5-aminosalicylsäure
WO2013059768A1 (en) * 2011-10-20 2013-04-25 Aptalis Pharma U.S., Inc. Therapeutic agents for treating gastrointestinal disorders associated with inflammation of the gastrointestinal tract
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
US20160175271A1 (en) * 2014-12-19 2016-06-23 Gavis Pharmaceuticals Rectal suppository for ulcerative colitis
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
BR112022008118A2 (pt) * 2019-10-31 2022-07-19 Scherer Technologies Llc R P Cápsula de supositório
KR20250042058A (ko) 2023-09-19 2025-03-26 한양대학교 산학협력단 염증성 장 질환 치료용 약학적 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689514A (en) 1969-05-21 1972-09-05 Schlueter Edelfett Suppository vehicle and process of making same
US4211777A (en) 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4374932A (en) 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
JPH0816051B2 (ja) 1988-12-07 1996-02-21 エスエス製薬株式会社 徐放性坐剤
US5629012A (en) 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
GB9201857D0 (en) 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
WO1997009035A1 (en) 1995-09-07 1997-03-13 Taisho Pharmaceutical Co., Ltd. Long-lasting composition for rectal administration
JPH09323934A (ja) 1996-05-31 1997-12-16 Kanebo Ltd 保存安定性の改善された坐剤
NZ500696A (en) 1997-04-01 2002-05-31 Borody Thomas J Methods and compositions for treating inflammatory bowel disease comprising mycobacterial agents, including macrolides
EP1017404B1 (en) 1997-09-26 2004-06-23 Medeva Europe Limited Pharmaceutical composition for the treatment of inflammatory bowel disease
JP4449213B2 (ja) 1997-10-08 2010-04-14 大正製薬株式会社 坐剤用組成物
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
EP1313697B1 (en) 2000-08-29 2005-11-30 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US20060104946A1 (en) 2002-08-23 2006-05-18 Zymogenetics, Inc. Method for treating inflammatory bowel disease
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
CA2565993C (en) 2004-05-27 2011-08-16 Antibe Therapeutics Inc. Salt of 4-or 5- aminosalicylic acid
CZ296169B6 (cs) 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
DE602005010899D1 (de) 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
US7250445B1 (en) 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP2009529053A (ja) 2006-03-07 2009-08-13 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の処置のための組成物および方法
CA2646021A1 (en) 2006-04-05 2007-10-05 Oklahoma Medical Research Foundation O-glycans in the treatment of inflammatory bowel disease and cancers
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
SG161259A1 (en) 2006-05-01 2010-05-27 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
US7842709B2 (en) 2006-09-08 2010-11-30 Ore Pharmaceuticals Inc. Method for treating inflammatory diseases of the digestive tract
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository

Similar Documents

Publication Publication Date Title
JP2013514979A5 (OSRAM)
ES2586057T3 (es) Comprimido de liberación sostenida que comprende pregabalina a través de un sistema de control de la liberación de dos fases
JP2010077141A5 (OSRAM)
JP2016520618A5 (OSRAM)
NZ708728A (en) Encased tamper resistant controlled release dosage forms
JP2016065086A5 (OSRAM)
JP2012529452A5 (OSRAM)
JP2013510123A5 (OSRAM)
WO2013016697A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2014504630A5 (OSRAM)
JP2013509429A5 (OSRAM)
ME02321B (me) Antivirusna jedinjenja
JP2014114295A5 (OSRAM)
JP2016504403A5 (OSRAM)
JP2014500861A5 (OSRAM)
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
JP2011037901A5 (OSRAM)
RU2015117251A (ru) Новые соединения
JP2018527305A5 (OSRAM)
JP2014218522A5 (OSRAM)
JP2020510000A5 (OSRAM)
JP2012505884A5 (OSRAM)
JP2014509655A5 (OSRAM)
JP2015007131A5 (OSRAM)
JP2009537554A5 (OSRAM)